Introduction
============

*Candida* species are a major group of fungal pathogens in humans, particularly among immunocompromised and hospitalized patients ([@B22]). *Candida albicans* inhabits various body surfaces like oral cavity, gastrointestinal tract, vagina, and skin of the healthy individuals as a commensal organism ([@B56]; [@B45]). Host-related factors can predispose the transformation of harmless *Candida* into an opportunistic pathogen, causing infection or candidiasis in superficial mucous surfaces which can progress into invasive mycoses ([@B82]). Foregoing factors include, but not limited to immuno-suppression, prolonged treatment with wide-spectrum antibiotics and chronic diseases ([@B60]; [@B96]). The epidemiology of invasive candidiasis varies geographically ([@B76]; [@B94]). It significantly increases the period of hospitalization, economic burden and mortality, especially in ICU patients or those under chemotherapy or with a history of abdominal surgery ([@B30]; [@B10]; [@B27]).

Only few classes of antifungals such as polyenes, azoles, echinocandins, allylamines, and flucytosine are available for the treatment of *Candida* infections ([@B104]). However, there are various undesirable properties, most importantly the dose-related toxicity in aforementioned antifungals ([@B15]). Ideally, an antifungal should have null or reduced toxicity toward human cells ([@B121]). For instance, amphotericin B is a polyene available for systemic administration, but its use has been limited due to its systemic side effects such as nephrotoxicity ([@B89]). Azole antifungals have some side effects associated with gastrointestinal, hepatic, and endocrinologic disorders and interfere with oxidative drug metabolism in the liver ([@B47]).

In addition, rising drug resistance is an inevitable problem. In particular, *Candida glabrata* and *Candida krusei* show intrinsic resistance to fluconazole, the drug of choice for AIDS patients ([@B49]; [@B109]; [@B102]). Drug resistance has already been reported for recently introduced echinocandin antifungal agents ([@B39]; [@B9]; [@B19]; [@B105]). Moreover, biofilm mode of *Candida* is known to be highly resistant to antifungal agents ([@B14]; [@B85]). Therefore, it is necessary to discover new antifungal agents or safer alternatives to improve the efficacy of treatment against *Candida* infections. In this regard, antifungal agents based on natural resources, such as phenolic compounds may be an alternative strategy to negate the rising antifungal drug resistance ([@B80]). This review attempts to critically analyze the possible use of phenolic acids as a therapeutic strategy against *Candida* infections.

Phenolic compounds are widely found in plant foods (fruits, cereal grains, legumes, and vegetables) and beverages (tea, coffee, fruits juices, and cocoa). The most common phenolic compounds are phenolic acids (cinnamic and benzoic acids), flavonoids, proanthocyanidins, coumarins, stilbenes, lignans, and lignins (**Figure [1](#F1){ref-type="fig"}**; [@B21]; [@B18]; [@B55]). The anti-*Candida* properties of phenolic compounds that have been widely reported in the literature include inactivation of enzyme production ([@B29]) and anti-biofilm effect ([@B29]; [@B106]).

![**Examples of phenolic compounds and main derivates classified as phenolic acids**.](fmicb-06-01420-g001){#F1}

Phenolic acids are derivatives of hydrocinnamic, hydrobenzoic, phenylacetic, and phenylpropionic acids (**Figures [1](#F1){ref-type="fig"}** and **[2](#F2){ref-type="fig"}**; [@B92]; [@B23]). Phenolic acids commonly exist as esters, glycosides or amides in nature, but not in their free form. The determining factor for characterization of phenolic acids is the number and the location of hydroxyl groups on the aromatic ring. Some natural sources are rich in phenolic acids and shown to possess a promising action against *Candida* (**Table [1](#T1){ref-type="table"}**). In this review, we discuss the anti-candidal activity of the phenolic acid compounds, possible mechanism of actions and future directions.

![**General chemical structures of the phenolic acids \[based on [@B92] and [@B23]\]**.](fmicb-06-01420-g002){#F2}

###### 

Phenolic acids derived from plants extracts showing activity against *Candida* sp.

  Plant                                      Phenolic acids found                                                                                                                     Type of extract                              Microorganism                                                                                                                                           MIC value μg/ml   MBC value μg/ml                Reference
  ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ------------------------------ -----------
  *Buchenavia tomentosa*                     Gallic acid                                                                                                                              Aqueous                                      *C. albicans* ATCC 18804 *C. tropicalis* ATCC 13803 *C. krusei* ATCC 6258 *C. glabrata* ATCC *C. parapsilosis* ATCC 22019 *C. dubliniensis* NCPF 3108   200--12500        6500 *C. krusei* (ATCC 6258)   [@B114]
  *Rosa rugosa*                              Protocatechuic, gallic, and *p*-coumaric acids                                                                                           Methanolic                                   *C. albicans* ATCC 10231 *C. parapsilosis* ATCC 22019                                                                                                   156               1250                           [@B88]
  *Teucrium arduini* L.                      Ferulic acid                                                                                                                             Ethanolic                                    *C. albicans* ATCC 10231                                                                                                                                4000              NR                             [@B57]
  *Potentilla* sp.                           Caffeic acid and ferulic acid                                                                                                            Acetonic and methaolic                       *C. albicans* ATCC 10231                                                                                                                                780--1560         NR                             [@B118]
  *Dimocarpus longan* Lour                   Gallic acid                                                                                                                              Spray-dried or Freeze-dried water            *C. krusei* ATCC 10231 *C. parapsilosis* ATCC 22019 *C. albicans* ATCC 90028 and clinical strains                                                       500--4000         NR                             [@B100]
  *Ligusticum mutellina L.*                  Gallic, *p*-OH-benzoic, caffeic, *p*-coumaric, and ferulic acids                                                                         Methanolic                                   *C. albicans* ATCC 10231 *C. parapsilosis* ATCC 22019                                                                                                   1250              2500                           [@B108]
  *Limonium avei*                            Caffeic, *m*-coumaric, *p*-coumaric, ferulic, isovanillic, *p*-methoxybenzoic, protocatechuic, sinapinic, and vanillic acids             Ethanolic                                    *C. albicans* ATCC 10231                                                                                                                                4000              \>4000                         [@B87]
  *Kitaibelia vitifolia*                     *p*-hydroxybenzoic, caffeic, syringic, *p*-coumaric, and ferulic acids                                                                   Ethanolic                                    *C. albicans* ATCC 10231                                                                                                                                15.62             NR                             [@B69]
  *Tamarix gallica L.*                       Gallic, synnapic, *p*-hydroxybenzoic, syringic, vanillic, *p*-coumaric, ferrulic, *trans*-2-hydroxycinnamic and *trans*-cinnamic acids   Hydromethanolic                              *C. kefyr, C. holmii, C. albicans, C. sake, C. glabrata*                                                                                                2000              NR                             [@B58]
  *Cirsium* sp.                              Caffeic, *p*-coumaric, ferulic, *p*-hidroxybenzoic, protocatechuic vanillic, and gallic acids                                            Aqueous                                      *C. albicans* ATCC 10231                                                                                                                                780--1560         6250 to \>50000                [@B79]
  *Olea europaea L.*                         Caffeic acid                                                                                                                             Aqueous                                      *C. albicans* CECT 1394                                                                                                                                 5000^∗^           NR                             [@B91]
  *Anogeissus latifolia*                     Gallic acid                                                                                                                              Hydroalcoholic after maceration with ether   *Candida albicans* (MTCC 183)                                                                                                                           7.28 μg/ml        NR                             [@B37]
  Berry (Cloudberry Raspberry, Strawberry)   Hydroxycinnamic acids                                                                                                                    Acetonic 70%                                 *Candida albicans* NCPF 3179                                                                                                                            1000 μg/ml        NR                             [@B86]

NR, not reported; \*IC
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Antifungal Activity of Phenolic Acids Against *Candida* Species
===============================================================

Natural extracts containing phenolic acids have demonstrated antifungal activity against *Candida* species (**Table [1](#T1){ref-type="table"}**). Phenolic acid derivatives isolated from these sources such as gallic, caffeic, cinnamic, benzoic, protocatechuic, and phenylacetic acids also have antifungal activity (**Table [2](#T2){ref-type="table"}**). However, the antifungal effect of the natural extracts may vary due to the differences in the quantity and the type of phenolic acid. In addition, the solvents used for extraction may also affect the antifungal effect. Moreover, other compounds present in natural extracts may act synergistically with phenolic acids to enhance the overall antifungal effect ([@B91]; [@B88]). Therefore, phenolic acids derived from different natural sources have highly variable MIC values against *Candida* (**Table [2](#T2){ref-type="table"}**). Hence, a clear understanding of the composition of phenolic acids present in the natural extract is important to assess its potential as an antifungal agent ([@B103]; [@B100]).

###### 

Evidences from literature regarding anti-*Candida* effect of phenolic acids.

  Molecule              Anti-*Candida* effect                                                                                                                                                                                                                                           Result found                                                                                                                Reference
  --------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -----------
  Gallic acid           Planktonic cells of *C. albicans* (ATCC 18804), *C. krusei* (ATCC 6258), *C. parapsilosis* (ATCC 22019), *C. dubliniensis* (NCPF 3108), and *C. glabrata* (ATCC 90030)                                                                                          MIC (μg/ml) respectively: 10000, 10000, 10000, 10000, 8                                                                     [@B114]
                        Planktonic cells and biofilm of *C. albicans* (ATCC 90028), *C. glabrata* (ATCC 2001), *C. parapsilosis* (ATCC 22019), and *C. tropicalis* (ATCC 750)                                                                                                           MIC (μg/ml) planktonic: \<156 μg/ml MIC (μg/ml) biofilm respectively: 5000, 1250, 625, 625                                  [@B5]
                        Planktonic cells (plate diffusion)                                                                                                                                                                                                                              MIC (mg cm^-3^): 2.5                                                                                                        [@B68]
                        Planktonic cells of *C. albicans* (ATCC 10231) and *C. tropicalis* (ATCC 750)                                                                                                                                                                                   MIC and MFC (μg/ml) respectively: 200, 200, 200, 100                                                                        [@B36]
                        Planktonic cells of *C. albicans* (ATCC 90028) and 5 clinical strains, *C. krusei* (ATCC 6258), and *C. parapsilosis* (ATCC 20019)                                                                                                                              MIC (μg/ml) respectively: 4000,4000,8000,4000, 16000, 16000, 8000, 4000                                                     [@B100]
                        Planktonic cells of *C. albicans* (ATCC 10231) and *C. parapsilosis* (ATCC 22019)                                                                                                                                                                               MIC (μg/ml) respectively: 8, 16                                                                                             [@B90]
                        Planktonic cells of *C. albicans* (ATCC 90028), *C. krusei* (ATCC 6258), and *C. parapsilosis* (ATCC 22019)                                                                                                                                                     MIC (μg/ml): 100                                                                                                            [@B63]
                        Biofilm of *C. albicans* (not cited strain)                                                                                                                                                                                                                     MIC (μg/ml): 1000                                                                                                           [@B117]
                        Planktonic cells of *C. albicans* (MTCC 183)                                                                                                                                                                                                                    MIC (μg/ml): 1.78                                                                                                           [@B37]
                        Planktonic cells of *C. albicans* (not cited strain)                                                                                                                                                                                                            Halo: 12 mm (100 μg on a sterile filter paper disk with 6 mm diameter)                                                      [@B33]
  Caffeic acid          Planktonic cells of *C. albicans* and inhibition of isocitrate lyase activity assay                                                                                                                                                                             MIC (μg/ml): 1000; inhibition of 91,5% of the isocitrate lyase enzyme activity                                              [@B17]
                        Planktonic cells and biofilm of *C. albicans* (ATCC 10231)                                                                                                                                                                                                      MIC (μg/ml): planktonic: 128; pre-formed, 4 and 24 h biofilm: 256                                                           [@B26]
                        Planktonic cells of *C. albicans* (ATCC 10231) and *C. parapsilosis* (ATCC 22019)                                                                                                                                                                               MIC (μg/ml) respectively: 8, 16                                                                                             [@B90]
  Protocatechuic acid   Planktonic cells of *C. albicans* (LMP709U)                                                                                                                                                                                                                     MIC and MFC (μg/ml) respectively: 156, 312                                                                                  [@B59]
                        Planktonic cells of *C. albicans* (10231) and *C. tropicalis* (ATCC 7349)                                                                                                                                                                                       MIC (μg/ml) respectively: 500, 400                                                                                          [@B98]
  Phenylacetic acid     Planktonic cells (plate diffusion) of *C. albicans* (clinical strains)                                                                                                                                                                                          Halo: 8--10.5 mm (20 μl of a 2000 ng/ml phenylacetic acid water solution on sterile filter paper disk with 6 mm diameter)   [@B70]
  Cinnamic acid         Immunoregulatory effect on monocytes activation against *C. albicans* (SC 5314)                                                                                                                                                                                 Significant reduce of *C. albicans* counts in 50 and 100 μg/ml                                                              [@B20]
                        Planktonic cells of *C. albicans* (ATCC 90028, ATCC 10231, PYCC 3436T) *C. parapsilosis* (ATCC 22019, PYCC 2545), *C. glabrata* (PYCC 2418T) *C. tropicalis* (PYCC 3097T), *C. krusei* (PYCC 3341), *C. lusitaniae* PYCC 2705T and synergism with antifungals   IC 50 (mmol l^-1^): 0.09 to 0.74; none synergism found                                                                      [@B31]
  Benzoic acid          Planktonic cells of *C. albicans* (ATCC 90028, ATCC 10231, PYCC 3436T) *C. parapsilosis* (ATCC 22019, PYCC 2545), *C. glabrata* (PYCC 2418T) *C. tropicalis* (PYCC 3097T), *C. krusei* (PYCC 3341), *C. lusitaniae* PYCC 2705T and synergism with antifungals   IC 50 (mmol l^-1^): 0.05--0.73 Synergism found to *C. albicans* with amphotericin and itraconazole                          [@B31]

The main *Candida* virulence factors are exoenzymes production, biofilm formation, adherence, and dimorphism ([@B116]; [@B81]; [@B119]). Few studies have demonstrated the influence of phenolic acids against these factors. Anti-biofilm effect of phenolic acids against *Candida* sp. was reported ([@B117]; [@B5]; [@B26]). However, the studies used only reference samples or did not cite the tested strain (**Table [2](#T2){ref-type="table"}**). The anti-biofilm effect of these molecules should be carried out with clinical isolates *in vitro* and *in vivo*, since the ultimate goal of using these molecules is to treat candidiasis and a wider range of strains could provide more reliable results. Besides that, it also has found an influence of caffeic acid derivate against the *Candida* dimorphism ([@B113]).

However, several studies described effect on *Candida* virulence factors of some others phenolic molecules. For instance, bisbibenzyl stimulates the synthesis of farnesol, an inhibitor of hyphae formation, via upregulation of *Dpp3* gene ([@B125]). Hence, bisbibenzyl may reduce *C. albicans* hyphal formation and affect biofilm formation. Moreover, anti-hyphae effect in *C. albicans* was also found following the treatment with epigallocatechin-gallate ([@B40]), licochalcone A, gladribin ([@B72]), and thymol ([@B12]). Additionally, eugenol reduces germ tube formation in *C. albicans* ([@B95]). Beyond that, several studies have shown anti-biofilm ([@B71]; [@B5]; [@B99]; [@B106]) and anti-adhesive ([@B32]; [@B99]; [@B106]) activities of phenolics against C*andida*.

The number of studies on other phenolic molecules on *Candida* virulence factors with interesting results inspires a carefully investigation of phenolic acids influence on these factors.

Mechanism of Action, Biological Pathways, and Synergism with Antifungal Agents of Phenolic Acids Against *Candida*
==================================================================================================================

In order to obtain some insights on the antifungal activity of phenolic acids, herein we compare the existing data along the lines of mechanism of action, synergy with known antifungal agents and others biological pathways (**Figure [3](#F3){ref-type="fig"}**).

![**Described mechanisms of action and biological pathways of some phenolic acids against *Candida*.** (1) [@B65]; (2) [@B17]; (3,4) [@B113]; (5) [@B20]; (6) [@B5]; (7) [@B26]; (8) [@B117].](fmicb-06-01420-g003){#F3}

Mechanisms of Action and Biological Pathways
--------------------------------------------

Phenolic acids such as ferulic and gallic acids are known to affect the cell membrane of Gram-positive and Gram-negative bacteria leading to a change in cell surface hydrophobicity and charge, ultimately causing leakage of cytoplasmic content ([@B11]). A similar effect has been suggested for the caffeic acid derivative on *Candida* cytoplasmatic membrane ([@B113]). Furthermore, a possible effect on the *C. albicans* cell wall has been shown for caffeic acid derivatives which may interfere with 1,3-β-glucan synthase ([@B65]).

It is noteworthy that polyene antifungals also cause pouring of cellular contents through direct binding to ergosterol, distorting the membrane function. Also, azole antifungal agents inhibit biosynthesis of ergosterol ([@B115]). No study on the effect of phenolic acid on the ergosterol composition or biosynthesis could be detected.

Mode of action of several others phenolic compounds provide some clues to deduce the mechanism of phenolic acids. For instance, isoquercetin ([@B123]), curcumin ([@B61]), and lariciresinol ([@B95]) can damage the *C. albicans* cell membrane. On the other hand, eugenol and methyleugenol cause considerable reduction in the ergosterol biosynthesis in *Candida* and subsequently affecting the cell membrane ([@B3]). Similar effect has been observed with epigallocatechin-3-gallate ([@B78]), thymol and carvacrol ([@B1]). Besides, cardanol demonstrated chitin-binding ability in *C. albicans* cell wall ([@B66]).

Few studies have found about others biological pathways of phenolic acids against *Candida*. Exemplifying, an *in vitro* immunoregulatory effect on monocytes against *C. albicans* by cinnamic acid ([@B20]) and a inhibition of *C. albicans* isocitrate lyase enzyme activity after treatment with caffeic acid ([@B17]) was reported. However, several studies have suggested that the other biological pathways and cellular targets of others phenolic compounds may be different from that of existing antifungal agents. Some phenolic compounds have shown to induce apoptotic mechanisms in *Candida*, thereby contributing to their antifungal activity ([@B126]). For instance, eugenol inhibits the cell cycle at G1, S, and G2-M phases in *C. albicans* and consequently induces apoptosis. Another phenolic compound, curcumin also induces apoptosis in *C. albicans*, by increasing the reactive oxygen species (ROS) and induction of *CaMCA1* gene expression ([@B13]). On the contrary, baicalein increases ROS causing perturbation in mitochondrial homeostasis in *C. krusei* without inducing apoptosis ([@B50]). Methyl chavicol seemed to induce aptotosis in *C. albicans* although the exact pathway is still not clear ([@B53]). Blocking effect of thymol, carvacrol ([@B4]) and baicalein ([@B44]) on the drug transporter pumps in *Candida* has been demonstrated using rhodamine 6G dye. Inhibition of eﬄux transporters results in accumulation of antifungal compounds inside the cell making *Candida* highly susceptible to the antifungal agent ([@B44]). These helpful anti-*Candida* biological pathways observed for phenolic molecules, mainly on the drug transporters pumps may contribute to elucidate the possible effects of phenolic acids against *Candida*.

Another aspect to be considered is that previous studies reported that some *Candida* species were able to metabolize phenolic acids ([@B74]; [@B73]). *C. parapsilosis* was able to grow in the presence of some phenolic acids after 3 days of cultivation. On the other hand, *C. tropicalis* was unable to grow in the presence of phenolic acids even after 14 days of cultivation ([@B73]). These evidences should be better investigated in the future. Further studies are warranted to obtain a deeper understanding of the mechanism of action and others biological pathways of phenolic acids on *Candida* cells.

Synergism with Existing Antifungal Agents
-----------------------------------------

Apart from rising antifungal resistance, there are other important limitations in the existing antifungal agents, such as inadequate spectrum of activity, poor bioavailability, small tolerance index, interactions with other drugs, inadequate pharmacokinetic profile, and considerable toxic effects ([@B62]; [@B93]). Although phytochemicals remain an important source for the discovery of new antifungal agents, micro-plate based *in vitro* screening assays have not shown higher effectiveness of plant extracts when compared to the existing antifungal agents with higher efficacy ([@B83]). Hence, in general, plant extracts with higher minimum inhibitory concentrations (MICs) such as 1000 μg/ml are considered ineffective ([@B75]).

Therefore, some studies have explored the possibility of synergistic activity of phenolic acids and existing antifungal agents in order to maximize the antifungal effect. It is a good strategy to study the synergistic effect when MIC values of phenolic acids against *Candida* are highly variable ([@B101]; [@B48]). Synergistic effect of benzoic acid with amphotericin B and itraconazole against *C. albicans* has been reported in literature ([@B31]; **Table [3](#T3){ref-type="table"}**). However, mechanism of this synergistic effect of phenolic acids and conventional antifungal agents is poorly understood. Therefore, it is important to examine similar synergistic effects shown by others phenolic compounds and conventional antifungal agents in order to obtain some insight.

###### 

Synergism of phenolic compounds with traditional antifungals in their action against *Candida albicans.*

  Compound                    Fluconazole                      Amphotericin B       Itraconazole   Others
  --------------------------- -------------------------------- -------------------- -------------- ------------
  2,5 Dihydroxybenzaldehyde   \_\_\_                           [@B31]               [@B31]         \_\_\_
  Baicalein                   [@B44]^†^                        [@B34]               \_\_\_         \_\_\_
  Benzoic acid^∗∗^            \_\_\_                           [@B31]               [@B31]         \_\_\_
  Benzyl benzoate             [@B126]^†^                       \_\_\_               \_\_\_         \_\_\_
  Butylated hydroxyanisole    [@B111]^†^                       [@B6]^∗^; [@B8]^∗^                  [@B110]^†^
  Carvacrol                   [@B4]^‡^                         \_\_\_               \_\_\_         \_\_\_
  Cinnamaldehyde              [@B54]                           \_\_\_               \_\_\_         \_\_\_
  Curcumin I                  [@B107]^‡^                       [@B107]              [@B107]^‡^     [@B107]^‡^
  Epigallocatechin-gallate    [@B41]^‡^                        [@B41]^‡^; [@B40]    [@B78]         [@B78]
  Eugenol                     [@B2]^‡^; [@B126]; [@B54]^∗∗∗^   \_\_\_               \_\_\_         \_\_\_
  Glabridin                   [@B64]                           \_\_\_               \_\_\_         [@B72]
  Honokiol                    [@B46]^†^                        \_\_\_               \_\_\_         \_\_\_
  Licochalcone A              \_\_\_                           \_\_\_               \_\_\_         [@B72]
  Methyleugenol               [@B2]^‡^                         \_\_\_               \_\_\_         \_\_\_
  Punicalagin                 [@B28]^†^                        \_\_\_               \_\_\_         \_\_\_
  Propyl gallate              [@B25]^†^                        [@B6]; [@B8]^∗^      [@B25]^†^      [@B112]^†^
  Thymol                      [@B38]^‡^; [@B31]; [@B4]^‡^      [@B38]; [@B31]       [@B31]         \_\_\_

∗

Ineffectiveness antifungal effect of phenolic alone;

∗∗

phenolic acid;

∗∗∗

performed on biofilm formation;

†

resistant strain;

‡

resistant and susceptible strains.

A promising synergism between phenolic compounds and fluconazole against resistant strains of *Candida tropicalis* was described recently ([@B24]). Several other studies have also demonstrated a significant synergism between other known antifungals and phenolic compounds against *C. albicans* (**Table [3](#T3){ref-type="table"}**). Some studies suggested that the synergism is due to the induction of apoptosis by an increase in the production of ROS. Hence, it was found that amphotericin B together with baicalein or curcumin increases the production of ROS ([@B107]; [@B34]). A similar effect has been observed with fluconazole and curcumin ([@B107]).

Another hypothesis for the aforementioned synergism is the association between folic acid cycle and ergosterol biosynthesis pathways of *C. albicans*. Hence, epigallocatechin-gallate, a phenolic compound was demonstrated to have a synergistic antifungal effect on *Candida* when combined with itraconazole or ketoconazole ([@B78]). Azoles directly inhibit the ergosterol biosynthesis while epigallocatechin-gallate has an antifolatic effect that indirectly affects the ergosterol biosynthesis. Epigallocatechin-gallate causes a depletion of the enzyme S-adenosylmethionine which in turn affects the enzyme Sterol C24 methyltransferase. Hence, lower production of C24 methyltransferase negatively affects the ergosterol biosynthesis. Direct and indirect effects on ergosterol biosynthesis explain the synergism between epigallocatechin-gallate and azoles ([@B78]).

Another study has shown that phenolic compounds such as thymol and carvacrol significantly decrease the expression levels of virulence genes *CDR1* and *MDR1* in fluconazole-resistant *C. albicans* ([@B4]). An *in vivo* study on systemic candidiasis in mice demonstrated that following the treatment with honokiol and fluconazole, the survival rate was 100% while a monotherapy showed only a survival rate of 80% to fluconazole and 20% to honokiol, respectively. Furthermore, the synergism of these two compounds led to a notable reduction in *C. albicans* counts in mouse kidneys compared with the fluconazole treatment alone ([@B46]). Similarly, mice treated with epigallocatechin-gallate and amphotericin B survived approximately 24 and 30 days longer when compared to the groups treated only with epigallocatechin-gallate or amphotericin B, respectively ([@B40]). Considering the foregoing evidence obtained for other phenolic compounds, it is likely that potential of synergism exists between known antifungal agents and phenolic acids and this possibility needs to be examined in future.

Safety of the Phenolic Acids *In vitro* and *In vivo*
-----------------------------------------------------

An 'ideal' antifungal agent for *Candida* infections should not have side effects or toxicity ([@B16]; [@B121]). However, in reality, all the antifungals currently in use have some side effects on gastrointestinal tract, liver and kidney ([@B120]; [@B7]). Therefore, practically one would expect to have some dose-related side effects from any new antifungal agent. It is imperative to understand this limitation in order to appreciate promising qualities of the drug under investigation. DNA-damaging effect of phenolic acids has been observed in p53R cell lines treated with gallic acid ([@B43]). Moreover, *in vivo* hepatotoxicity was observed in rats when given a diet supplemented with more than 200 mg/kg/day of gallic acid ([@B35]). In addition, hematological disorders, as well as liver and kidney weight increase were observed in rats fed with 0.6--5% of gallic acid daily for 13 weeks ([@B84]).

A potential carcinogenicity was observed on the fore-stomach of rats when fed with a powdered diet containing 0.4% of caffeic acid for up to 28 weeks ([@B42]). The clastogenic power of caffeic and cinnamic acids have been described *in vitro* ([@B67]). Subcronic administration of protocatechuic acid (0.1% in drinking water) for 60 days has shown a possible liver and kidney toxicity in mice ([@B77]). Sodium benzoate and sodium phenylacetate have been used in the treatment of acute hyperammonaemia and are derived from benzoic acid and phenylacetic acid respectively. Inappropriate doses of both substances may cause plasma acidosis, hypotension, cerebral edema and other neurotoxical effects, sometimes even death of patients ([@B51]; [@B97]). Phenylacetic acid can also affect the osteoblastic functions *in vitro* and increase cell proliferation in the alveolar region ([@B52]; [@B122]). Sodium and potassium benzoates could be clastogenic, mutagenic and cytotoxic to human lymphocytes *in vitro* ([@B124]). Therefore, is imperative to examine the dose-related toxicity of phenolic acids in a series of comprehensive *in vitro*, *in vivo* and clinical studies before administration as an antifungal agent.

Conclusion
==========

Phenolic acids demonstrate considerable antifungal properties against *Candida*. Previous studies have shown phenolic acid compounds possess considerable anti-adhesion, anti-biofilm effects, and inhibitory activity on morphogenesis and exoenzyme production of *Candida* species. However, hitherto no clear mechanism of action of phenolic acids on *Candida* cells and virulence factors has been described compared to the existing antifungal agents. Interestingly, there is substantial evidence of the synergistic effect of phenolic acids and existing antifungal agents which may become a promising anti-candidal strategy. However, more studies are in demand for a conclusive statement regarding their role. Therefore, we propose that more comprehensive studies are mandatory to obtain evidence regarding the suitability of the use of phenolic acids as a successful antifungal agent in future.
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